Eli Lilly Co. world headquarters in Indianapolis —Jetcityimage—Getty Images Eli Lilly is reporting promising results for the first drug to target three hormones related to weight loss—not just one or two, as current GLP-1 drugs do. In a press release, the company reported that its experimental injectable drug, retatrutide, helped people who were overweight or obese to lose up to 28% of their body weight over 1.5 years compared to people receiving placebo.